Article
DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles.
Journal of virology - 1 Aug 2008
Cox Kara S, Clair James H, Prokop Michael T, Sykes Kara J, Dubey Sheri A, Shiver John W, Robertson Michael N, Casimiro Danilo R
Abstract excerpt
Results from Merck's phase II adenovirus type 5 (Ad5) gag/pol/nef test-of-concept trial showed that the vaccine lacked efficacy against human immunodeficiency virus (HIV) infection in a high-risk population. Among the many questions to be explored following this outcome are whether (i) the Ad5 vaccine induced the quality of T-cell responses necessary for efficacy and (ii) the lack of efficacy in the Ad5 vaccine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
